Methotrexate 50 MG (Trexonate)
Product Name : Methotrexate
Generic Name : Trexonate
Formulation : Injection
Available Pack Size : 1’s
Available Strengths : 50 mg
Registrations : Bangladesh
Product Information
Trexonate (Methotrexate) 50mg is a folate antagonist (antimetabolite) used, at very different doses depending on the condition, either as part of multi-drug chemotherapy regimens for certain cancers or as a once-weekly immunosuppressant for rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and severe psoriasis. It works by blocking dihydrofolate reductase, an enzyme needed for DNA synthesis and cell replication, which slows the growth of rapidly dividing cells. Manufactured for the Bangladesh market and globally supplied by Mediaid Pharmacy with worldwide shipping.
Critical Safety Notice: Weekly vs. Daily Dosing
For rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and psoriasis, Methotrexate is dosed ONCE WEEKLY, not daily. Fatal medication errors have occurred when Methotrexate was mistakenly taken or administered every day instead of once a week for these conditions. This is now included in the FDA boxed warning for Methotrexate products. Oncology dosing is entirely different and follows a specific, physician-directed protocol. Always confirm the exact dose, frequency, and indication with the prescribing physician before every administration, and never assume a daily schedule.
Basic Product Information of Trexonate (Methotrexate) 50mg
| Brand Name | Trexonate (Methotrexate) — please confirm brand/generic naming before publishing; see note above |
| Generic Name | Methotrexate INN |
| Drug Class | Folate Antagonist / Antimetabolite (Dihydrofolate Reductase Inhibitor) |
| Available Strengths | 50mg per vial |
| Formulation | Sterile Injection (Solution for Intravenous, Intramuscular, Subcutaneous, or Intrathecal Use, per indication) |
| Pack Size | 1’s (single vial per pack). The dose actually given from the vial varies enormously by indication — see Dosage section. |
| Primary Indication | Selected Cancers (as part of combination chemotherapy), Rheumatoid Arthritis, Polyarticular JIA, Severe Psoriasis |
| Regulatory Approvals | USFDA Approved (neoplastic diseases as part of combination regimens; adult rheumatoid arthritis; paediatric polyarticular JIA; adult severe psoriasis). EMA Approved (equivalent indications). |
| Originator/Reference Brands | Methotrexate has been marketed under various brand names globally (for example, Otrexup, Rasuvo, Trexall, and generic injectable methotrexate); first approved 1953. |
| Manufacturer | [Manufacturer name to be confirmed], Bangladesh |
| Global Supplier | Mediaid Pharmacy, Worldwide Shipping Available |
| Registration | Registered in Bangladesh |
| Storage Conditions | Store as directed on the pack, generally refrigerated or below 25 degrees Celsius depending on formulation, protected from light. This is a hazardous drug — follow applicable special handling, storage, and disposal procedures. Keep out of the reach of children. |
How Trexonate (Methotrexate) Works
Trexonate contains Methotrexate, which inhibits dihydrofolate reductase, the enzyme responsible for converting dihydrofolate into tetrahydrofolate. Tetrahydrofolate is essential as a carrier of one-carbon units in the synthesis of purine nucleotides and thymidylate, the building blocks of DNA. By blocking this step, Methotrexate interferes with DNA synthesis, repair, and cellular replication.
Rapidly proliferating tissues, such as malignant tumour cells, bone marrow, and the lining of the mouth and gut, are the most sensitive to this effect, which is why Methotrexate is effective as chemotherapy at higher doses. At much lower, once-weekly doses, Methotrexate also has an immunomodulatory effect that reduces inflammation in autoimmune conditions such as rheumatoid arthritis and psoriasis, although the precise mechanism in these conditions is not fully understood.
Trexonate is given by injection — the route (intravenous, intramuscular, subcutaneous, or intrathecal) and the setting (hospital chemotherapy unit versus a weekly self-administered injection at home) depend entirely on the indication and the treating physician’s prescribed protocol.
Indications for Trexonate (Methotrexate)
Trexonate (Methotrexate) is indicated for the following, at very different doses and schedules:
|
Selected Cancers (Oncology Dosing) As part of multi-drug chemotherapy regimens for cancers including certain leukaemias, lymphomas, osteosarcoma, gestational trophoblastic neoplasia, and other malignancies, per disease-specific, physician-directed protocols. |
Rheumatoid Arthritis For adults with severe, active rheumatoid arthritis, dosed once weekly. |
|
Polyarticular Juvenile Idiopathic Arthritis For paediatric patients with pJIA affecting multiple joints, dosed once weekly. |
Severe Psoriasis For adults with severe, recalcitrant, disabling psoriasis not adequately responsive to other forms of therapy, dosed once weekly. |
Benefits of Trexonate (Methotrexate) 50mg
|
Decades of Established Use First approved in 1953, Methotrexate remains a cornerstone therapy in both oncology and rheumatology, backed by an extensive body of clinical experience. |
Injectable Route for Reliable Dosing Injection bypasses variable oral absorption, which can be an advantage for patients who do not respond adequately or tolerate oral methotrexate well. |
Foundational Combination Chemotherapy Agent A core component of numerous established multi-drug regimens across several cancer types. |
|
Effective Once-Weekly Immunosuppression A well-established, once-weekly treatment option for controlling inflammation in rheumatoid arthritis, pJIA, and severe psoriasis. |
Affordable Access Offers an affordable route to a well-established antimetabolite therapy for both oncology and rheumatology use. |
WHO-GMP and cGMP Certified Manufactured under strict WHO-GMP, cGMP, and ISO-certified standards, ensuring every batch of Trexonate meets consistent quality and safety requirements. |
Dosage and Administration of Trexonate (Methotrexate)
Rheumatoid arthritis (adults): Starting dose of 7.5mg once weekly, by intramuscular, subcutaneous, or intravenous injection, adjusted by the physician to achieve optimal response. Given once weekly, never daily.
Polyarticular JIA (paediatric): Starting dose of 10mg/m² once weekly, by subcutaneous or intramuscular injection, adjusted by the physician. Given once weekly, never daily.
Severe psoriasis (adults): 10mg to 25mg once weekly, by intramuscular or intravenous injection, adjusted by the physician. Given once weekly, never daily.
Oncology (neoplastic disease): Dosing varies enormously by cancer type and protocol, from roughly 10 mg/m² up to several thousand mg/m² intravenously as part of a multi-drug regimen. High-dose regimens require leucovorin (folinic acid) rescue and close monitoring, exactly as specified in the treating oncologist’s protocol.
Who administers it: For oncology use, Trexonate is prepared and given by trained healthcare professionals in a hospital or chemotherapy setting. For rheumatoid arthritis, pJIA, or psoriasis, a physician may, in selected cases, train the patient or caregiver to self-administer the once-weekly injection at home; this should only happen with explicit training and a clear, written weekly schedule.
Folate supplementation: Folic acid or folinic acid is typically prescribed alongside low-dose weekly Methotrexate for rheumatoid arthritis, pJIA, and psoriasis, to reduce certain side effects, without reducing efficacy.
Renal impairment: Methotrexate is cleared by the kidneys, and reduced kidney function significantly increases toxicity risk. Dose reduction or avoidance is required depending on the degree of impairment, as determined by the treating physician.
Monitoring and Key Toxicities
Regular monitoring is essential during Trexonate treatment, regardless of indication. Your healthcare provider will monitor complete blood counts for bone marrow suppression (anaemia, leukopenia, thrombocytopenia, or, rarely, pancytopenia), liver function for hepatotoxicity, and renal function, since reduced kidney function increases the risk of severe toxicity. Monitoring also includes watchfulness for mouth sores, diarrhoea, or vomiting that may require treatment to be withheld, respiratory symptoms that could indicate pulmonary toxicity, and skin reactions, which can occasionally be severe.
Pregnancy status must be verified before starting Trexonate in patients of reproductive potential, and effective contraception is required during and for a period after treatment for both female and male patients, as Methotrexate can cause fetal harm. Report any fever, unusual bruising or bleeding, mouth ulcers, persistent cough or breathlessness, or yellowing of the skin or eyes to your doctor immediately.
Drug Interactions and Important Information
Several common medications can significantly increase Methotrexate toxicity by reducing its clearance from the body, including NSAIDs (including at low weekly RA doses, where use requires caution and monitoring), proton pump inhibitors, probenecid, and certain penicillins. Trimethoprim-sulfamethoxazole and other antifolate-pathway antibiotics can increase the risk of severe bone marrow suppression when combined with Methotrexate.
Fluid collections such as ascites or pleural effusion can delay Methotrexate clearance and increase toxicity risk, requiring dose adjustment. Live vaccines should be avoided during treatment, and other immunisations may be less effective. Always inform your physician of all medications, supplements, and herbal products you are currently taking before starting Trexonate.
Side Effects and Precautions
|
Common Side Effects Nausea and vomiting Mouth sores (stomatitis) Fatigue Headache Diarrhoea Elevated liver enzymes |
Serious Warnings and Precautions Fatal medication errors from incorrect daily (instead of weekly) dosing for RA, pJIA, and psoriasis. Bone marrow suppression, which can cause serious infection or bleeding. Hepatotoxicity, including fibrosis or cirrhosis with chronic use. Severe, occasionally fatal skin reactions. Pulmonary toxicity, including interstitial pneumonitis. Embryo-fetal toxicity, including fetal death. Contraindicated in pregnancy for non-oncology indications. |
Who Should Use Trexonate (Methotrexate)?
Trexonate is suitable for patients with a confirmed cancer diagnosis requiring Methotrexate as part of an oncologist-directed multi-drug regimen, adults with severe, active rheumatoid arthritis, paediatric patients with polyarticular JIA, and adults with severe psoriasis not adequately controlled by other therapies. It is prescribed by oncologists, rheumatologists, and dermatologists experienced in antimetabolite therapy. Baseline blood counts, liver and kidney function, and pregnancy status should be assessed before starting treatment, whatever the indication.
Manufacturer
Trexonate (Methotrexate) is manufactured in Bangladesh under strict WHO-GMP, cGMP, and ISO-certified standards. [Please confirm the exact manufacturer name so it can be added here and in the specs table above.]
Global Supplier: Mediaid Pharmacy with Worldwide Shipping
Mediaid Pharmacy is a trusted global supplier of oncology and immunosuppressant medications. We ensure Trexonate (Methotrexate) is accessible to patients and healthcare providers worldwide through reliable worldwide shipping. Whether you are located in South Asia, the Middle East, Africa, Europe, or beyond, Mediaid Pharmacy provides fast and reliable delivery with full order support. Contact us directly via WhatsApp, phone, or WeChat for pricing, availability, and delivery enquiries.
Why Choose Trexonate (Methotrexate) from Mediaid Pharmacy?
Trexonate offers a well-established antimetabolite therapy for both oncology and rheumatology use, backed by more than seven decades of clinical experience with Methotrexate worldwide. Manufactured under WHO-GMP and cGMP standards and distributed globally by Mediaid Pharmacy, Trexonate gives patients and healthcare providers worldwide access to this foundational medication at an accessible price. Given the significant dosing risks specific to this medicine, Mediaid Pharmacy strongly encourages every patient and prescriber to confirm the exact dose, frequency, and route with the treating physician before every single administration.
Frequently Asked Questions About Trexonate (Methotrexate)
What is Trexonate (Methotrexate) used for?
Trexonate (Methotrexate) is used in two very different ways: as part of multi-drug chemotherapy regimens for certain cancers, at doses set by an oncologist’s protocol, and as a once-weekly treatment for rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and severe psoriasis, at much lower doses. It works by blocking an enzyme needed for cell replication.
Is Methotrexate taken daily or weekly?
For rheumatoid arthritis, polyarticular JIA, and psoriasis, Methotrexate is given once weekly, never daily. Taking or administering it daily by mistake for these conditions has caused fatal medication errors, which is why this warning now appears in the FDA boxed warning. Oncology dosing follows a completely different, protocol-specific schedule set by the treating oncologist. Always double-check the exact schedule with the prescribing physician.
What strength and pack size is Trexonate available in?
Trexonate is available as a 50mg injection vial, supplied as 1’s (one vial per pack). The actual dose drawn up and given from the vial depends heavily on the indication — commonly a small fraction of the vial for weekly rheumatoid arthritis or psoriasis dosing, versus protocol-specific doses for cancer treatment.
What are the side effects of Trexonate (Methotrexate)?
Common side effects include nausea, mouth sores, fatigue, headache, and diarrhoea. Serious risks include bone marrow suppression, liver toxicity, severe skin reactions, and lung toxicity, alongside the critical risk of fatal errors from incorrect daily dosing in non-oncology use. Regular blood, liver, and kidney monitoring is required throughout treatment. Always consult your physician for a complete assessment of your individual risks and benefits.
Is Trexonate (Methotrexate) safe during pregnancy?
No. Methotrexate can cause fetal harm, including fetal death, and is contraindicated in pregnant women being treated for rheumatoid arthritis or psoriasis. In cancer treatment, it may be used in pregnancy only if the potential benefit outweighs the risk to the fetus, as judged by the treating oncologist. Effective contraception is required for both female and male patients during and for a period after treatment. Please consult your physician before starting treatment if pregnancy is a possibility.
Can Trexonate be taken with NSAIDs or other medications?
NSAIDs, proton pump inhibitors, probenecid, certain penicillins, and trimethoprim-sulfamethoxazole can all increase Methotrexate toxicity and require caution or physician guidance. Always review your complete medication list, including over-the-counter pain relievers and supplements, with your prescribing physician before starting or continuing Trexonate.
Can I order Trexonate (Methotrexate) online with worldwide shipping?
Yes. Mediaid Pharmacy supplies Trexonate (Methotrexate) 50mg globally with worldwide shipping. Contact us via WhatsApp, phone, or WeChat at +8801773428128 or email us at info@mediaidpharmacy.com to enquire about pricing, availability, and delivery to your country.
Order Trexonate (Methotrexate) 50mg with Worldwide Shipping
Phone / WhatsApp / WeChat: +8801773428128 | Email: info@mediaidpharmacy.com
